The off-label use of GLP-1 drugs like Ozempic and Mounjaro for weight loss is rapidly growing in Europe, creating a booming private market and raising public health concerns. Countries like Italy, Greece, Portugal, Spain, Germany, and Poland are experiencing significant increases in spending and demand, despite varying regulations and reimbursement policies. The trend is fueled by social media and a desire for quick weight loss solutions, leading to a shadow market where individuals pay out-of-pocket for these medications. Teljes cikk (Euronews.com)